SSA
VVOS icon

Schonfeld Strategic Advisors’s Vivos Therapeutics VVOS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,100
Closed -$623K – 2446
2023
Q4 		$623K Buy
+50,100
New +$430K ﹤0.01% 1202
2021
Q4 		– Sell
-1,378
Closed -$139K – 2576
2021
Q3 		$139K Buy
+1,378
New +$145K ﹤0.01% 1866

Other funds holding VVOS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schonfeld Strategic Advisors's VVOS Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Vivos Therapeutics (VVOS) in Q1 2024, closing a stake of 50,100 shares — an estimated $623K sold.

Schonfeld Strategic Advisors first reported a position in VVOS in Q3 2021 and held it in 2 quarters. The position peaked at $623K in Q4 2023. 16 funds tracked by Wall St. Rank hold VVOS as of Q1 2024.

  • Schonfeld Strategic Advisors reported no remaining Vivos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 50,100 Vivos Therapeutics shares in Q1 2024, an estimated $623K.
  • Schonfeld Strategic Advisors first reported a position in Vivos Therapeutics in Q3 2021 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Vivos Therapeutics position peaked at $623K in Q4 2023.
  • 16 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.